Mirati Therapeutics Announces IND Submission of MRTX849 to Treat NSCLC & CRC
Shots:
- The IND submission under FDA is in response to onset P-I/II clinical trial for MRTX849- to evaluate its safety- PK & tolerability
- With the IND acceptance- the trial will use an accelerated titration design with single patient cohorts and intra-patient dose for MRTX849 & P-II expansion cohorts will enroll patients with +ve KRAS G12C mutations
- MRTX849 PO is a KRASi and further stops G12C mutation. The P-II study portion in NSCLC & CRC patients will provide proof-of-concept (expected in 2019) and support for its accelerated approval
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
